ClinicalTrials.Veeva
Menu

Find clinical trials for Ovarian Cancer in Louisville, KY

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Ovarian Epithelial Carcinoma
Cancer
Carcinoma
Endometrial Cancer
Fallopian Tube Cancer
Breast Cancer
Triple Negative Breast Cancer

Ovarian Cancer trials near Louisville, KY, USA:

ONC-392 and Pembrolizumab in Platinum Resistant Ovarian Cancer (PRESERVE-004)

efficacy with the combination of a next generation anti-CTLA-4 antibody, ONC-392, and anti-PD-1 antibody, pembrolizumab, in platinum resistant ovarian...

Enrolling
Fallopian Tube Cancer
Ovarian Cancer
Drug: ONC-392
Drug: Pembrolizumab

Phase 2

OncoC4

Louisville, Kentucky, United States and 20 other locations

Olaparib Monotherapy in Patients with BRCA Mutated Ovarian Cancer following First Line Platinum Based Chemotherapy....

Active, not recruiting
Advanced Ovarian Cancer
FIGO Stage III-IV
Drug: Olaparib 300mg tablets

Phase 3

AstraZeneca
AstraZeneca

Louisville, Kentucky, United States and 176 other locations

in participants with platinum-resistant high-grade epithelial ovarian cancer, primary peritoneal, or fallopian tube cancer...

Active, not recruiting
Epithelial Ovarian Cancer
Peritoneal Cancer
Drug: Paclitaxel
Drug: Pegylated liposomal doxorubicin

Phase 3

ImmunoGen
ImmunoGen

Louisville, Kentucky, United States and 213 other locations

following response to front-line treatment in newly diagnosed ovarian cancer patients. Response to treatment will be analyzed based...

Active, not recruiting
Epithelial Ovarian Cancer
Fallopian Tube Cancer
Drug: Placebo Oral Tablet
Drug: Rucaparib

Phase 3

pharmaand

Louisville, Kentucky, United States and 237 other locations

preliminary antitumor activity of NKT3447 in adult subjects with cyclin E1 (CCNE1) amplified ovarian cancer at the RDEs selected i...

Enrolling
Solid Tumor
Advanced Ovarian Carcinoma
Drug: NKT3447

Phase 1

NiKang Therapeutics

Louisville, Kentucky, United States and 7 other locations

The primary objective of this study is to evaluate progression-free survival (PFS) by blinded independent central review (BICR) in patients treated w...

Active, not recruiting
Ovarian Neoplasm
Fallopian Tube Neoplasms
Drug: Relacorilant 150 mg once daily (QD)
Drug: Nab-paclitaxel 100 mg/m^2

Phase 3

Corcept Therapeutics
Corcept Therapeutics

Louisville, Kentucky, United States and 116 other locations

This research is designed to determine if experimental treatment with Antibody-drug conjugate, AZD5335, alone, or in combination with anti-cancer...

Enrolling
Ovarian Cancer
Lung Adenocarcinoma
Drug: Bevacizumab
Drug: AZD5335

Phase 1, Phase 2

AstraZeneca
AstraZeneca

Louisville, Kentucky, United States and 45 other locations

This study will assess the safety and efficacy of DPX-Survivac and low dose cyclophosphamide with pembrolizumab in subjects with selected advanced an...

Active, not recruiting
Bladder Cancer
Non-small Cell Lung Cancer
Other: DPX-Survivac
Drug: Pembrolizumab

Phase 2

Immunovaccine

Louisville, Kentucky, United States and 22 other locations

the Recommended Phase 2 dose (RP2D) for PF-07104091 as a single agent in participants with advanced or metastatic small cell lung, breast and ovarian...

Active, not recruiting
Breast Cancer
Small Cell Lung Cancer
Drug: PF-07104091 monotherapy dose expansion (ovarian)
Drug: PF-07104091 + palbociclib + fulvestrant

Phase 1, Phase 2

Pfizer
Pfizer

Louisville, Kentucky, United States and 51 other locations

to find out if ZW171 is safe and can treat participants with advanced (locally advanced \[inoperable\] and/or metastatic) mesothelin-expressing cancers...

Enrolling
Mesothelin-expressing Advanced Cancers
Drug: ZW171

Phase 1

Zymeworks

Louisville, Kentucky, United States

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems